Table 3.
Descriptive statistics for DLBCL Cohort 1, observation period ≤1year after index date.
| Variable | All subjects (N = 4501) | Outcome (N = 1646) | No outcome (N = 2855) |
|---|---|---|---|
| Age (mean, SD) | 56.33 (13.74) | 57.12 (13.74) | 55.88 (14.84) |
| Age group (%) | |||
| 0-4 | 0 | 0 | 0 |
| 5-9 | 0 | 0 | 0 |
| 10-14 | 0 | 0 | 0 |
| 15-19 | 2 | 2 | 1 |
| 20-24 | 2 | 2 | 2 |
| 25-29 | 2 | 2 | 2 |
| 30-34 | 3 | 2 | 3 |
| 35-39 | 3 | 3 | 4 |
| 40-44 | 5 | 6 | 5 |
| 45-49 | 9 | 9 | 9 |
| 50-54 | 13 | 12 | 13 |
| 55-59 | 16 | 16 | 15 |
| 60-64 | 20 | 21 | 19 |
| 65-69 | 9 | 11 | 8 |
| 70-74 | 6 | 6 | 6 |
| 75-79 | 9 | 9 | 9 |
| 80-84 | 2 | 2 | 2 |
| Sex: male (%) | 45 | 44 | 45 |
| Sex: female (%) | 55 | 56 | 55 |
| Medical history: general (%) | |||
| Acute respiratory disease | 30 | 30 | 30 |
| Attention deficit hyperactivity disorder | 1 | 1 | 1 |
| Long-term liver disease | 5 | 5 | 5 |
| Long-term obstructive lung disease | 7 | 7 | 7 |
| Crohn’s disease | 1 | 1 | 1 |
| Dementia | 0 | 0 | 0 |
| Depressive disorder | 10 | 10 | 10 |
| Diabetes mellitus | 17 | 18 | 17 |
| Gastroesophageal reflux disease | 17 | 17 | 16 |
| Gastrointestinal hemorrhage | 5 | 5 | 5 |
| Human immunodeficiency virus infection | 2 | 1 | 2 |
| Hyperlipidemia | 40 | 40 | 40 |
| Hypertensive disorder | 44 | 46 | 43 |
| Lesion of liver | 1 | 1 | 1 |
| Obesity | 8 | 8 | 7 |
| Osteoarthritis | 19 | 20 | 18 |
| Pneumonia | 9 | 11 | 8 |
| Psoriasis | 0 | 1 | 0 |
| Renal impairment | 9 | 11 | 8 |
| Rheumatoid arthritis | 3 | 4 | 2 |
| Schizophrenia | 0 | 0 | 0 |
| Ulcerative colitis | 1 | 1 | 1 |
| Urinary tract infectious disease | 10 | 11 | 10 |
| Viral hepatitis C | 2 | 2 | 2 |
| Visual system disorder | 32 | 33 | 31 |
| Medical history: cardiovascular disease | |||
| Atrial fibrillation | 5 | 6 | 5 |
| Cerebrovascular disease | 3 | 3 | 4 |
| Coronary arteriosclerosis | 11 | 12 | 11 |
| Heart disease | 35 | 38 | 33 |
| Heart failure | 6 | 6 | 5 |
| Ischemic heart disease | 6 | 6 | 7 |
| Peripheral vascular disease | 16 | 17 | 16 |
| Pulmonary embolism | 2 | 2 | 2 |
| Venous thrombosis | 7 | 8 | 7 |
| Medical history: neoplasms (%) | |||
| Hematologic neoplasm | 70 | 75 | 67 |
| Malignant lymphoma | 100 | 100 | 100 |
| Malignant neoplasm of anorectum | 0 | 0 | 0 |
| Malignant neoplastic disease | 100 | 100 | 100 |
| Malignant tumor of breast | 1 | 1 | 1 |
| Malignant tumor of colon | 0 | 0 | 0 |
| Malignant tumor of lung | 0 | 0 | 0 |
| Malignant tumor of urinary bladder | 0 | 0 | 0 |
| Primary malignant neoplasm of prostate | 1 | 1 | 1 |
| Medication use (%) | |||
| Agents acting on the renin-angiotensin system | 22 | 22 | 21 |
| Antibacterials for systemic use | 64 | 67 | 61 |
| Antidepressants | 16 | 17 | 16 |
| Anti-epileptics | 10 | 12 | 9 |
| Anti-inflammatory and antirheumatic products | 21 | 22 | 21 |
| Antineoplastic agents | 29 | 39 | 24 |
| Antipsoriatics | 1 | 1 | 1 |
| Antithrombotic agents | 24 | 27 | 22 |
| Beta blocking agents | 17 | 18 | 17 |
| Calcium channel blockers | 11 | 11 | 11 |
| Diuretics | 19 | 22 | 18 |
| Drugs for acid-related disorders | 29 | 33 | 27 |
| Drugs for obstructive airway diseases | 26 | 27 | 25 |
| Drugs used in diabetes | 10 | 10 | 10 |
| Immunosuppressants | 6 | 9 | 5 |
| Lipid modifying agents | 24 | 24 | 24 |
| Opioids | 44 | 49 | 42 |
| Psycholeptics | 48 | 53 | 45 |
| Characteristic | |||
| Charlson comorbidity index | |||
| Mean | 4 | 4 | 4 |
| Minimum | 2 | 2 | 2 |
| 25th percentile | 2 | 2 | 2 |
| Median | 3 | 3 | 3 |
| 75th percentile | 5 | 5 | 5 |
| Maximum | 19 | 19 | 17 |
| CHADS2Vasc for stroke prediction | |||
| Mean | 2 | 2 | 2 |
| Minimum | 0 | 0 | 0 |
| 25th percentile | 1 | 1 | 1 |
| Median | 2 | 2 | 2 |
| 75th percentile | 3 | 3 | 3 |
| Maximum | 9 | 9 | 9 |
| DCSI | |||
| Mean | 2 | 2 | 2 |
| Minimum | 0 | 0 | 0 |
| 25th percentile | 0 | 0 | 0 |
| Median | 1 | 1 | 1 |
| 75th percentile | 4 | 4 | 4 |
| Maximum | 13 | 13 | 12 |
Abbreviations: DLBCL, diffuse large B-cell lymphoma; DCSI, Diabetes Complications Severity Index.
Means (SD) or median (IQR) are given for continuous variables; frequencies (percentages) are given for categorical variables: Observation period ⩽1 year after index date.